AP-PA02

BIOLOGICAL2 trials

Sponsors

Armata Pharmaceuticals, Inc.

Conditions

Cystic FibrosisLung InfectionLung Infection PseudomonalNon-cystic Fibrosis BronchiectasisPseudomonasPseudomonas Aeruginosa

Phase 1

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

CompletedNCT04596319

Armata Pharmaceuticals, Inc.Cystic Fibrosis, Lung Infection, Lung Infection Pseudomonal +2

Start: 2020-12-22End: 2022-12-14Updated: 2024-01-31

Phase 2

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

CompletedNCT05616221

Armata Pharmaceuticals, Inc.Lung Infection, Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa

Start: 2023-01-10End: 2024-08-08Updated: 2026-01-05

Related Papers

Optimizing phage therapy with antidefense proteins acquired from the environment

Frontiers in Microbiology2026-06-03